CorMedix (CRMD) Earnings Date & Reports

Key Takeaways

• CorMedix (CRMD) is expected to report third-quarter 2026 results on November 11, 2026, before the market opens, with a conference call scheduled for November 12.
• Consensus estimates call for revenue of roughly $52.8 million and a net loss of approximately $0.09 per share, reflecting a sharp expected decline from the prior-year quarter's $104.3 million in revenue and $1.26 diluted EPS.
• The anticipated pullback is largely driven by DefenCath's transition from TDAPA (Transitional Drug Add-on Payment Adjustment, a temporary Medicare reimbursement program) to lower post-TDAPA pricing, which management has flagged for the second half of 2026.
• CorMedix reaffirmed full-year 2026 revenue guidance of $325 million to $345 million and raised adjusted EBITDA guidance to $125 million to $140 million when it last reported in August 2026.
• Analysts maintain a Moderate Buy consensus rating with an average price target near $14.62, well above recent trading levels.
• For additional coverage, explore Major News, Today's Price Move, Price Targets, and Forecast pages for this ticker.
• Interested in automated trading insights? Explore Trending AI Robots for data-driven market signals.

Earnings Context and Why It Matters

CorMedix's third-quarter report carries unusual weight because it marks the first full quarter reflecting DefenCath's move from the temporary TDAPA reimbursement period into the post-TDAPA add-on phase. During TDAPA, the company captured elevated per-unit pricing that powered record revenue and profitability; as that benefit phases out, investors are bracing for lower net pricing even as underlying volume demand continues. Management has already guided for this transition, but the market is watching closely to see whether volume growth and the acquired Melinta portfolio can offset the pricing reset. The quarter will test the durability of CorMedix's newly diversified, profitable business model following its August 2025 Melinta acquisition.

Earnings Expectations

Analysts expect CorMedix to report third-quarter 2026 revenue near $52.8 million, down roughly 49% from $104.3 million a year earlier, alongside a consensus net loss of about $0.09 per share compared with $1.26 diluted EPS in the prior-year period. These figures reflect a deliberate, well-telegraphed reset: in the second half of 2026, DefenCath transitions from TDAPA to a post-TDAPA add-on reimbursement amount that results in materially lower net selling prices per unit. For context, CorMedix posted $101.9 million in revenue and $0.29 diluted EPS in the second quarter of 2026, beating estimates, and has topped consensus EPS in seven of its last eight quarters. Beyond the headline figures, investors will scrutinize DefenCath unit volumes, Melinta portfolio sales, operating-expense discipline, and any updated commentary on full-year 2026 guidance of $325 million to $345 million in revenue and $125 million to $140 million in adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a measure of core operating profitability).

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For those tracking earnings catalysts like CorMedix's upcoming report, it offers a streamlined way to surface relevant opportunities across the healthcare and biopharmaceutical landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but constructive. The anticipated year-over-year revenue and EPS declines are widely understood to be a reimbursement artifact rather than a demand problem, and the stock has already repriced through much of 2026 as the TDAPA-to-add-on transition approached. Still, the gap between the roughly $14.62 average analyst price target and recent trading levels signals that many investors believe the market is undervaluing the company's volume trajectory and pipeline optionality. Key risk factors include greater-than-expected pricing pressure in the post-TDAPA phase, any slowdown in DefenCath ordering patterns, and slower progress on Medicare Advantage contracting, which management has excluded from 2026 guidance but views as a meaningful longer-term growth lever.

Forward Outlook and Key Factors to Monitor

Beyond the headline numbers, investors should watch several forward-looking signals. First is the trajectory of DefenCath volume and whether order patterns remain consistent with management's post-TDAPA forecasts; a pilot program with a newly signed large dialysis organization, covering roughly 200 clinics, is expected to begin in the third quarter, with potential expansion into 2027.

Second, reimbursement clarity matters. Management has indicated that, based on current CMS (Centers for Medicare & Medicaid Services) calculation methodology, the post-TDAPA add-on amount could rise significantly in 2027, potentially supporting a higher net selling price per unit next year relative to second-half 2026 estimates.

Third, keep an eye on the pipeline. CorMedix has reported positive Phase III ReSPECT data for REZZAYO in the prophylaxis of invasive fungal disease, with an sNDA (supplemental New Drug Application, a filing seeking approval for a new use of an already-approved drug) submission planned for the third quarter of 2026 and potential FDA action in the first half of 2027. Success there would open a large additional market and diversify the company further beyond hemodialysis.

Finally, monitor expense discipline and cash generation. With a strong balance sheet, an integrated Melinta portfolio, and an expanding commercial organization, the company's ability to hold operating costs in check while funding pipeline investment will be central to sustaining the profitability narrative through the reimbursement transition.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations